Can a fruit compound clear old cells and fight aging?
NCT ID NCT06431932
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests fisetin, a natural compound found in strawberries and apples, in healthy young adults and older people with multiple chronic diseases. Participants take fisetin or a placebo for two days and are followed for up to three months. The goal is to see if fisetin safely removes senescent (aging) cells and reduces inflammation, which could help manage age-related health problems.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- fisetin (a natural compound from fruits and vegetables)
- What this could lead to
- If it works, this could point toward a treatment that reduces chronic inflammation and age-related diseases by clearing old, damaged cells.
- What could go wrong
- This is an early Phase 1/2 trial with only 60 participants, so results may not apply broadly. Fisetin's effects on humans are still uncertain, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre
RECRUITINGHvidovre, 2650, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test